Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat for HbF Induction in Severe Sickle Cell Disease
NCT01000155Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2009
- Primary completion
- Oct 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in sickle cell disease (SCD), sponsored by Dana-Farber Cancer Institute. Started Oct 2009; status: terminated.
02
Drugs
vorinostat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01000155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000155.